Polyarteritis nodosa: lessons from 25 years of experience.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 13 06 2018
accepted: 08 10 2018
pubmed: 13 11 2018
medline: 15 6 2019
entrez: 13 11 2018
Statut: ppublish

Résumé

Polyarteritis nodosa is a necrotising vasculitis of predominantly medium size vessels. The present study aimed to summarise the characteristics of PAN patients, and also analyse the trend of decreasing PAN frequency in the last 25 years. PAN patients followed up between 1990 and 2015 were included. The demographics, clinical findings and outcomes were retrospectively evaluated. One hundred thirty-three patients, including 66 children, were enrolled in the study. Among 133 patients, 86 (64.7%) had fever, 108 (81.2%) had skin involvement, 54 (40.6%) had renal involvement, 43 (32.3%) had neurological involvement, 32 (24.1%) had gastrointestinal involvement, 10 (7.5%) had cardiac involvement, 6 (4.5%) had pulmonary involvement. The median (minimum-maximum) leukocyte count, erythrocyte sedimentation rate and C-reactive protein levels at the time of diagnosis were 10400 (6100-32000)/mm3, 58 (2-132) mm/h and 5.22 (0-46) mg/dL, respectively. All patients were ANCA negative. Hepatitis serology was analysed in 121 patients and found positive in 13 of them. MEFV mutations were screened among 65 patients, 24 of them had mutations in at least one allele. Biopsy was performed in 109 patients and angiography was performed in 92 patients. The number of PAN patients declined significantly after 2010. 9 patients were re-categorised as DADA2 after 2014 and no patient were diagnosed with FMF+PAN after 2008. Our results suggest a decrease in PAN in our country which may be due to improved healthcare and dissecting mimicking diseases. Further prospective studies with prolonged follow-up could help us to better understand the disease characteristics.

Identifiants

pubmed: 30418125
pii: 13063

Substances chimiques

Intercellular Signaling Peptides and Proteins 0
MEFV protein, human 0
Pyrin 0
Adenosine Deaminase EC 3.5.4.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-56

Auteurs

Hafize Emine Sönmez (HE)

Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey.

Berkan Armağan (B)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey.

Gizem Ayan (G)

Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Turkey.

Kenan Barut (K)

Department of Paediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Turkey.

Ezgi Deniz Batu (ED)

Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey.

Abdulsamet Erden (A)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey.

Serdal Uğurlu (S)

Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Turkey.

Yelda Bilginer (Y)

Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey.

Özgur Kasapçopur (Ö)

Department of Paediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Turkey.

Ömer Karadağ (Ö)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey.

Sule Apras Bilgen (SA)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey.

Huri Özdoğan (H)

Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Turkey.

Seza Ozen (S)

Department of Paediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, and Hacettepe University Vasculitis Center, Ankara, Turkey. sezaozen@hacettepe.edu.tr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH